[
    [
        {
            "time": "2018-04-20",
            "original_text": "Analysts’ Recommendations for Eli Lilly & Co. on April 20",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Recommendations",
                    "Analysts"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for Eli Lilly & Co. on April 20",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "Pre-Market Earnings Report for April 24, 2018: VZ, KO, MMM, LMT, UTX, CAT, LLY, NEE, BIIB, TRV, SHW, FCX",
            "features": {
                "keywords": [
                    "Earnings",
                    "Pre-Market",
                    "Report"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "diversified"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pre-Market Earnings Report for April 24, 2018: VZ, KO, MMM, LMT, UTX, CAT, LLY, NEE, BIIB, TRV, SHW, FCX",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN",
            "features": {
                "keywords": [
                    "Earnings",
                    "Q1",
                    "Drug/Biotech"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Revenue Growth",
                    "1Q18"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "Upcoming Earnings: CAT, LLY And BA Report This Week",
            "features": {
                "keywords": [
                    "Earnings",
                    "CAT",
                    "LLY",
                    "BA"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "industrial goods",
                    "pharmaceuticals",
                    "aerospace"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Upcoming Earnings: CAT, LLY And BA Report This Week",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings",
            "features": {
                "keywords": [
                    "Analysts",
                    "Estimates",
                    "Eli Lilly",
                    "1Q18"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "Merck’s Relebactam Met Primary Endpoints in Phase 3 Study",
            "features": {
                "keywords": [
                    "Merck",
                    "Relebactam",
                    "Phase 3",
                    "Endpoints"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck’s Relebactam Met Primary Endpoints in Phase 3 Study",
                "Correlation": 3,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings",
            "features": {
                "keywords": [
                    "Analysts",
                    "Predict",
                    "GlaxoSmithKline",
                    "1Q18"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "Elanco Announces Addition of Chief Financial Officer",
            "features": {
                "keywords": [
                    "Elanco",
                    "CFO",
                    "Addition"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "animal health"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Elanco Announces Addition of Chief Financial Officer",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose",
            "features": {
                "keywords": [
                    "FDA",
                    "Panel",
                    "Lilly-Incyte",
                    "Arthritis Drug",
                    "Lower Dose",
                    "Higher Dose"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]